Showing results (231-240 of 263) with videos related to
Sort By:
Pageof 27
PDA Journal of Pharmaceutical Science and Technology|September 15, 2019
Advancing Biologics Development Programs with Legacy Cell Lines: Advantages and Limitations of Genetic Testing for Addressing Clonality Concerns Prior to Availability of Late Stage Process and Product Consistency DataPaul Wu, Taymar Hartman, Louise Almond, et al.Biological Psychiatry|September 25, 2007
Cingulate-precuneus interactions: a new locus of dysfunction in adult attention-deficit/hyperactivity disorderF Xavier Castellanos, Daniel S Margulies, Clare Kelly, et al.Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|October 5, 2019
Moving Towards Hepatitis C Microelimination Among People Living With Human Immunodeficiency Virus in Australia: The CEASE StudyMarianne Martinello, Jasmine Yee, Sofia R Bartlett, et al.The Pediatric Infectious Disease Journal|September 18, 2025
Long-term Impact of Invasive Meningococcal Disease in Australian Adolescents and Young AdultsMark McMillan, Jim Buttery, Margaret Angliss, et al.JACC. Clinical Electrophysiology|November 20, 2020
First-in-Human Chronic Implant Experience of the Substernal Extravascular Implantable Cardioverter-DefibrillatorIan Crozier, Haris Haqqani, Emily Kotschet, et al.Health Science Reports|August 24, 2022
Patterns and correlates of hepatitis C virus phylogenetic clustering among people living with HIV in Australia in the direct-acting antiviral era: A molecular epidemiology study among participants in the CEASE cohortSofia R Bartlett, Andrey Verich, Joanne Carson, et al.Antiviral Research|May 18, 2010
Biochemical characterization of the inhibition of the dengue virus RNA polymerase by beta-d-2'-ethynyl-7-deaza-adenosine triphosphateDerek R Latour, Andreas Jekle, Hassan Javanbakht, et al.European Journal of Gastroenterology & Hepatology|January 3, 2020
Cost effectiveness of treatment models of care for hepatitis C: the South Australian state-wide experienceJeyamani Ramachandran, Billingsley Kaambwa, Kate Muller, et al.The New England Journal of Medicine|August 2, 2023
Selective Inhibition of NaV1.8 with VX-548 for Acute PainJim Jones, Darin J Correll, Sandra M Lechner, et al.Journal of Hepatology|May 23, 2021
Sofosbuvir/velpatasvir for 12 vs. 6 weeks for the treatment of recently acquired hepatitis C infectionGail V Matthews, Sanjay Bhagani, Marc Van der Valk, et al.Pageof 27